New asthma pill shows promise in early trial for stubborn symptoms

NCT ID NCT07191535

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 33 times

Summary

This study tests a new drug called linvemastat for adults with moderate-to-severe asthma that is not fully controlled by standard inhalers. The drug targets an enzyme linked to lung inflammation. About 135 participants will receive either a low dose, high dose, or placebo for 16 weeks while continuing their usual medications. Researchers will measure changes in lung function and asthma flare-ups to see if linvemastat offers additional control.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ASTHMA (DIAGNOSIS) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.